clofibrate has been researched along with perfluorooctane sulfonic acid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Haughom, B; Spydevold, O | 1 |
| Campos, CR; Cannon, RE; Chan, GN; Evans, RA; Miller, DS; More, VR; Oliver, KD | 1 |
2 other study(ies) available for clofibrate and perfluorooctane sulfonic acid
| Article | Year |
|---|---|
The mechanism underlying the hypolipemic effect of perfluorooctanoic acid (PFOA), perfluorooctane sulphonic acid (PFOSA) and clofibric acid.
Topics: Alkanesulfonates; Alkanesulfonic Acids; Animals; Caprylates; Cells, Cultured; Cholesterol; Cholesterol Esters; Clofibrate; Fatty Acids; Fluorocarbons; Hypolipidemic Agents; Kinetics; Liver; Male; Rats; Rats, Wistar; Reference Values; Triglycerides | 1992 |
PPAR-α, a lipid-sensing transcription factor, regulates blood-brain barrier efflux transporter expression.
Topics: Alkanesulfonic Acids; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Blood-Brain Barrier; Brain; Capillaries; Clofibrate; Fasting; Fluorocarbons; Gene Expression Regulation; Linoleic Acid; Male; Mice, Inbred C57BL; Mice, Knockout; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Oxazoles; PPAR alpha; Rats, Sprague-Dawley; Tyrosine | 2017 |